Impact of IL-2 on Treatment Tolerance in Patients With High-Risk Neuroblastoma Treated With Dinutuximab Beta-Based Immunotherapy

類似資料

• PD-1 blockade augments anti-neuroblastoma immune response induced by anti-GD(2) antibody ch14.18/CHO
  著者:: Siebert, Nikolai, 等
  出版事項: (2017)
• Nivolumab and dinutuximab beta in two patients with refractory neuroblastoma
  著者:: Ehlert, Karoline, 等
  出版事項: (2020)
• Co-expression of IL-15 enhances anti-neuroblastoma effectivity of a tyrosine hydroxylase-directed DNA vaccination in mice
  著者:: Marx, Madlen, 等
  出版事項: (2018)
• Low CD4⁺/CD25⁺/CD127⁻ regulatory T cell- and high INF-γ levels are associated with improved survival of neuroblastoma patients treated with long-term infusion of ch14.18/CHO combined with interleukin-2
  著者:: Troschke-Meurer, Sascha, 等
  出版事項: (2019)
• Neuroblastoma patients with high-affinity FCGR2A, -3A and stimulatory KIR 2DS2 treated by long-term infusion of anti-GD(2) antibody ch14.18/CHO show higher ADCC levels and improved event-free survival
  著者:: Siebert, Nikolai, 等
  出版事項: (2016)